Table 4.
Outcomes data based on the 2 most common somatic alterations (>10%). For every outcome, patients with the somatic alteration of interest are compared to wild type, or patients with somatic data available but without the somatic alteration of interest (N = 50).
| Somatic alteration | De novo metastatic disease (%) | High-volume (CHAARTED) (%) | Undetectable PSA (%) | CRPC (%) | |||||
|---|---|---|---|---|---|---|---|---|---|
| TP53 (N = 12) | Mutant | 67% | P = .59 | 82% | P = .83 | 27% | P = .16 | 50% | P = .30 |
| 30% | |||||||||
| WT | 58% | 53% | 51% | ||||||
| CDK12 (N = 6) | Mutant | 67% | P = .30 | 50% | P = .53 | 50% | P = .82 | 50% | P = .45 |
| WT | 59% | 60% | 45% | 34% | |||||
WT: wild type (somatic data available and mutation of interest is absent); CRPC: castrate resistant prostate cancer.